Novo Nordisk can't keep up with demand as sales of its weight-loss drugs soar
The Danish company's revenues have surged thanks to an explosion in popularity for its diabetes and obesity drugs Ozempic and Wegovy.
The Danish company's revenues have surged thanks to an explosion in popularity for its diabetes and obesity drugs Ozempic and Wegovy.